Shanghai Runda Medical Technology Co Ltd
SSE:603108
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (1.3), the stock would be worth ¥15.06 (12% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.1 | ¥13.43 |
0%
|
| 3-Year Average | 1.3 | ¥15.06 |
+12%
|
| 5-Year Average | 1.2 | ¥14.18 |
+6%
|
| Industry Average | 2.7 | ¥32.27 |
+140%
|
| Country Average | 1.9 | ¥23.24 |
+73%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Shanghai Runda Medical Technology Co Ltd
SSE:603108
|
8.1B CNY | 1.1 | -51.4 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 84.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.4B USD | 1.9 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
124B USD | 1.8 | 33.6 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 5.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
326.9B CNY | 5 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | 2 | -119.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.4B USD | 3.2 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.1B USD | 7 | 46.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.8B USD | 1.6 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.8B USD | 8.2 | 29.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.9 |
| 70th Percentile | 3.4 |
| Max | 1 129 391.6 |
Other Multiples
Shanghai Runda Medical Technology Co Ltd
Glance View
Shanghai Runda Medical Technology Co Ltd, nestled in the bustling heart of China's economic capital, stands as a quintessential example of a company thriving at the crossroads of innovation and healthcare. Established as a key player in medical diagnostics, Runda Medical focuses on the distribution and provision of high-quality medical devices and diagnostic solutions. Their business model revolves around integrating advanced technology with healthcare needs, enabling medical institutions to enhance their diagnostics capabilities through cutting-edge equipment and robust system support. The company holds a substantial portfolio of both proprietary and partnered products, allowing healthcare providers faster and more precise diagnostic insights. This is bolstered by a dependable supply chain and comprehensive after-sales service, ensuring that medical institutions can rely on consistent performance from their systems. Runda Medical's financial engine is powered predominantly by its distribution networks and strategic partnerships with leading medical technology firms worldwide. By leveraging these alliances, the company can offer a wide range of products that serve various segments of the medical industry, including hospitals, clinics, and laboratories. Revenue flows are primarily generated through the sale of medical devices such as automated analyzers, imaging systems, and diagnostic reagents — all designed to meet the growing demands for efficiency and accuracy in healthcare diagnosis. Moreover, their value proposition is further enhanced by the company's investments in customer education and training, ensuring that the end-users of their systems are not just purchasers but long-term partners in progress, thereby solidifying Runda Medical's reputation as a steadfast ally in China's healthcare landscape.